ABSTRACT. Group B streptococci (GBS) localizing in the lungs of infant piglets is killed in part by an oxygen radicaldependent mechanism (Bowdy BD, Marple SL, Pauly TH, Coonrod JD, Gillespie MN: Am Rev Respir Dis 141: [648][649][650][651][652][653] 1990). The source of bactericidal oxygen radicals is unknown, but cyclooxygenation of arachidonic acid, an initial event in prostanoid synthesis, is accompanied by substantial oxygen radical generation. Because blockade of prostaglandin H synthase (cyclooxygenase) with indomethacin prevents GBS-induced pulmonary hypertension, we reasoned that the salutary effect of indomethacin might be associated with a reduction in the efficacy of bactericidal activity directed against GBS. To address this possibility, the distribution and viability of "'In-labeled GBS (10' colony forming units/kg/min i.v. for 15 min) were assessed in lungs and livers of control piglets, piglets treated with indomethacin (1 mg/kg), and piglets treated with OKY-046 (10 mg/kg), an inhibitor of thromboxane synthase that also forestalls GBS-induced pulmonary hypertension. Relative to control animals, indomethacin treatment increased pulmonary GBS uptake with no change in bacterial distribution into the liver. OKY-046 failed to influence pulmonary bacterial uptake but promoted a substantial increase in GBS depositing in the liver. In contrast to its effects on pulmonary bacterial deposition, indomethacin failed to increase lung bacterial viability relative to control animals. Indomethacin also was without effect on hepatic bacterial viability. OKY-046 failed to influence pulmonary bacterial viability but markedly augmented hepatic GBS viability to the extent that significant bacterial proliferation occurred. Both indomethacin and OKY-046 abolished GBS-induced pulmonary hypertension by preventing the increase in pulmonary arterial pressure and decrease in cardiac output. Viewed collectively, these observations suggest that oxygen radicals derived from cyclooxygenation of arachidonic acid in GBS-treated piglets do not contribute to microbicidal activity directed against the organism. (Pediatr Res 31: [14] [15] [16] [17] 1992) Abbreviations GBS, group B streptococci HBSS, Hanks' balanced salt solution cfu, colony forming units
Ppa, pulmonary arterial pressure
Multiple lines of evidence indicate that cyclooxygenase products of arachidonic acid metabolism, particularly thromboxane AZ, are important mediators of the early pulmonary hypertensive response to GBS sepsis. Blockade of prostaglandin H synthase (cyclooxygenase) with indomethacin or blockade of thromboxane synthase with dazmegrel forestalls increases in Ppa and pulmonary vascular resistance provoked by GBS in young piglets (1, 2) . Thromboxane also accumulates in systemic blood after challenge with GBS or other gram-positive organisms (3) . Administration of a thromboxane mimetic elevates Ppa in a manner similar to the response to GBS (4) .
We have recently reported that a substantial proportion of intravascular GBS localizes in lung tissue, probably in pulmonary intravascular macrophages, where the organism is killed in part by an oxygen radical-dependent mechanism (5, 6) . The cellular and biochemical sources of bactericidal oxygen radicals are unknown, but several pathways for oxygen radical generation within phagocytes have been described (7) . In light of the probable role of eicosanoids in GBS-induced pulmonary hypertension, it is significant that bactericidal oxygen radicals are generated as a consequence of arachidonic acid metabolism (8) . Cyclooxygenation of arachidonic acid via prostaglandin H synthase has been shown to produce superoxide anion (9) . The action of lipoxygenase on arachidonic acid also generates superoxide anion, but the rate of production is considerably lower than that associated with prostaglandin H synthase (9) . Finally, metabolism of arachidonic acid to epoxides by cytochrorne P-450 generates superoxide anion (lo), but virtually nothing is known of the kinetics and importance of this pathway.
Indomethacin and other nonsteroidal anti-inflammatory agents prevent superoxide anion generation secondary to the action of prostaglandin H synthase on arachidonic acid (8) . To determine if oxygen radicals from this source contribute to pulmonary microbicidal activity directed against GBS, the present study tested the hypothesis that indomethacin increases viability of the organism. The impact of the thromboxane synthase inhibitor OKY-046 on pulmonary GBS disposition also was examined because blockade of arachidonic acid metabolism at this step in the pathway leaves intact the generation of bactericidal oxygen radicals (8) but prevents hemodynamic abnormalities evoked by GBS (2) . In addition to addressing the source of microbicidal oxygen radicals, these experiments may have clinical implications; inasmuch as blockade of prostaglandin H synthase or thromboxane synthase may comprise a potential therapeutic approach to sepsis-related pulmonary hypertension (1-3), the possibility should be considered that along with suppressing development of pulmonary hypertension, such agents may also impair host bacterial defense.
MATERIALS AND METHODS
serially diluted in HBSS, streaked on blood agar plates, and Culture and preparation of "'In-labeled GBS. Cultures of GBS (Streptococcus agalactiae, serotype 11, American-type Culture Collection no. 138 13, Difco Laboratories, Detroit, MI) were inoculated in brain-heart infusion broth containing 7% heatinactivated FCS and grown to log phase at 37°C under a 5% C02 atmosphere. The medium was centrifuged at 2000 x g for 15 min, and the pellet washed and resuspended in HBSS. Concentration of bacteria in the slurry was determined by quantitative culture and by relating OD to cfu. Procedures described previously were used to radiolabel the organisms with "'In (5, 6) . In brief, GBS suspended in HBSS were centrifuged, the pellet was resuspended in HBSS, and 1 mL containing approximately 2.5 x 10" cfu was transferred to a microfuge tube and mixed with 15 pCi "'In-oxine. The tube was vortexed three times at 5-min intervals and then centrifuged at 15 000 x g for 2 min. The resulting pellet was resuspended in 1 mL HBSS. This procedure (vortexing, centrifugation, and resuspension) was repeated four times. After the 3rd cycle, bacteria were resuspended in 50 mL of medium (instead of 1 mL) and allowed to stand at room temperature for 1.5 h to remove any remaining soluble or loosely adherent indium. After the last centrifugation, the pellet was resuspended in HBSS to a bacterial concentration lo9 cfu/mL.
Animal preparation and experimental protocol. Piglets ranging in age from 5 to 10 d and in weight from 1.7 to 3.1 kg were anesthetized with 50 mg/kg sodium pentobarbital intraperitoneally and placed on a servo-controlled heat exchanging pad to maintain body temperature at 38 k 1°C. A tracheal cannula was inserted and the animals were ventilated (Fi02 = 0.3) with a Harvard small animal ventilator (Kent, England). A polyethylene catheter was inserted into the jugular vein and advanced into the pulmonary artery for monitoring of Ppa. Additional catheters were inserted into the femoral vein and artery for bacterial administration and for monitoring of systemic arterial pressure. Pressures were monitored using Statham transducers (Oxnard, CA) in conjunction with a Grass model 7 polygraph (Quincy, MA). Cardiac output was measured in duplicate by thermodilution using an Edwards Laboratory (model 9250A, Santa Anna, CA) cardiac output computer and a 5F thermodilution catheter. Arterial blood gases in 1-mL blood samples taken from the arterial catheter were determined using an Instrumentation Laboratories model 2 13 blood gas analyzer (Lexington, MA). During a 30-min equilibration period, the ventilator was adjusted to attain baseline Po2, Pco2, and pH values of 15.33-13.34 kPa (1 15-130 torr), 4.93-5.59 kPa (37-42 torr), and 7.35-7.45 kPa, respectively. Ventilator settings were not changed after initiation of the experiment. Animals were divided into three groups of five to seven, with each animal receiving a 15-min i.v. infusion of lo8 cfu GBS/kg/ min. One group served as the control and, 10 min before GBS, received an i.v. bolus injection of the vehicle for indomethacin, 100 mM sodium carbonate. The second and third groups were treated identically, except that they received slow i.v. bolus injections (over approximately 5 min) of 1 mg/kg indomethacin and 10 mg/kg OKY-046, respectively. Doses of indomethacin and OKY-046 were selected on the basis of reports in the literature documenting their efficacy to inhibit thromboxane synthesis (4, 11) . The vehicle for OKY-046 was sterile saline; controls were not performed for this treatment group.
Assessment of bacterial deposition and viability. Animals were killed with an overdose of sodium pentobarbital 45 min after termination of the 15-min bacterial infusion. Lungs and liver were removed aseptically, weighed, and homogenized in 4-mL sterile HBSS. Radioactivity was determined in an aliquot of homogenate using a Packard gamma counter (Downers Grove, IL). Bacterial deposition was quantitated as the percentage of radioactivity distributing into a particular organ relative to the total amount of radioactivity recovered in the organs of interest.
T o assess bacterial viability, an aliquot of homogenate was Differences between experimental groups were assessed using a one-or two-way analysis of variance, depending on the variable measured, combined with Dunnett's test. Differences were considered significant when p s 0.05.
RESULTS
Time-dependent changes in mean Ppa, cardiac output, and arterial Po2 evoked by GBS in control piglets and in animals treated with indomethacin or OKY-046 are shown in Figure 1 . As expected, GBS given to control animals caused prompt increases in mean Ppa, decreases in cardiac output, and decreases in arterial Po2. These changes tended to moderate on termination . , . , . , . , . , . of the 15-min GBS infusion but failed to return completely to baseline values within the 45-min postinfusion period. Also as expected, both indomethacin and OKY-046 prevented the hypertensive response and decline in arterial PO,. Ppa failed to increase above baseline values, and cardiac output did not fall in either drug-treated group. The impact of indomethacin and OKY-046 on distribution of GBS into the lungs and liver is shown in Figure 2 . Relative to control animals, indomethacin treatment was associated with an increase in pulmonary GBS uptake with no change in bacterial distribution into the liver. OKY-046 failed to influence pulmonary bacterial uptake but promoted a substantial increase in GBS depositing in the liver. Figure 3 illustrates the effects of indomethacin and OKY-046 on bacterial viability in the lungs and liver. In contrast to our hypothesis, indomethacin failed to increase bacterial viability in the lung relative to control animals. Conversely, a trend (0.1 > p > 0.05) toward decreased pulmonary bacterial viability was noted. Bacterial viability in the liver was unaffected by indomethacin treatment. OKY-046 also failed to increase pulmonary bacterial viability, although a trend toward this response was evident. In contrast, hepatic GBS viability was markedly increased by OKY-046, to the extent that significant bacterial proliferation was observed.
DISCUSSION
The present study tested the hypothesis that indomethacin, an inhibitor of prostaglandin H synthase known to prevent sepsis- Bacterial distribution, calculated as described in Materials and Methods, was determined 45 min after termination of a 15-min infusion of GBS. Note that the scales of the vertical axes differ between panels A and B. * = Significantly different from control group at p < 0.05. related pulmonary hypertension, impairs bactericidal activity directed against GBS in intact piglets. We reasoned that if prostaglandin H synthase-derived oxygen radicals were a significant component of the microbicidal mechanism, then indomethacin would augment bacterial viability. In contrast to our expectations, we found that indomethacin failed to increase either lung or liver bacterial viability. In fact, a trend toward the opposite response was noted; bacterial viability tended to be reduced in lungs from indomethacin-treated animals. As reported by others (e.g. Ref. l) , indomethacin prevented the hypertensive response to GBS, thus confirming efficacy of the drug to inhibit prostaglandin H synthase. From these observations we conclude that prostaglandin H synthase-derived oxygen-free radicals do not contribute significantly to bactericidal activity directed against GBS in intact piglets. Nevertheless, because the oxygen radical burden cannot be directly or accurately measured in either lung or liver, this conclusion must be viewed with some caution. It also is appropriate to note that despite the apparent lack of involvement of cyclooxygenase-derived oxygen-free radicals, the bactericidal role of other oxygen radical-generating pathways of arachidonic acid metabolism, including lipoxygenase and cytochrome P-450 (9,10), cannot be excluded on the basis of the present experiments.
In contrast to its lack of impact on lung bacterial viability, indomethacin was associated with an increase in pulmonary deposition of GBS. This favorable combination of increased pulmonary bacterial deposition, in concert with a tendency for increased microbicidal activity, suggests that the impact of indomethacin, and (perhaps) other prostaglandin H synthase in-hibitors on host microbial defense mechanisms, will not present serious obstacles to the use of such agents in septic neonates with pulmonary hypertension. Nevertheless, at least two caveats should be emphasized: First, the impact of indomethacin on host bacterial defense could be fundamentally different in species whose cellular microbicidal mechanisms differ from those of piglets. In this context, relative to piglets, human lungs exhibit a low density of pulmonary intravascular macrophages (1 3), cells that may play a central role in clearance of intravascular bacteria (6, 14) . Second, other pharmacologic aspects of prostaglandin H synthase blockade, particularly its impact on the ductus arteriosis, must be considered as this therapeutic strategy is explored.
Although both indomethacin and OKY-046 prevent GBSinduced pulmonary hemodynamic alterations, ostensibly through inhibition of thromboxane synthesis, there are reasons to suspect that they might have divergent effects on host microbicidal mechanisms. For example, although prostaglandin H synthase activity is associated with substantial superoxide anion generation, this does not occur with thromboxane synthase (8) . Indomethacin, but not OKY-046, might be expected to alter oxygen radical-mediated bacterial killing. Inhibition of prostaglandin H synthase also has been shown to redirect archidonic acid metabolism to favor synthesis of lipoxygenase products (I 5); this shift does not likely occur with thromboxane synthase inhibition. An increased burden of lipoxygenase products, which occurs with indomethacin but not OKY-046, could augment recruitment of phagocytes to the lung and thereby increase pulmonary entrapment and killing of bacteria independent of hemodynamic changes. A comparison between the effects of indomethacin and OKY-046 could thus provide information on the relative contribution of hemodynamic and nonhemodynamic factors as determinants of pulmonary microbicidal activity in septic piglets.
Indomethacin increased pulmonary bacterial deposition and tended to decrease bacterial viability, whereas OKY-046 failed to change pulmonary bacterial deposition and tended to increase viability, yet both agents prevented the pulmonary hypertensive response. One explanation for the disparate effects on bacterial distribution is that these agents have divergent actions on blood flow distribution, with pulmonary blood flow increased by indomethacin but not by OKY-046. Counter to this possibility, a recent preliminary report indicates that indomethacin fails to alter cardiac output in anesthetized piglets, at least over a 1-h period corresponding to the duration of the present study (16) . The effects of OKY-046 on cardiac output and organ blood flow in infant animals have not, to our knowledge, been reported. A second explanation for the divergent effects of indomethacin and OKY-046 on bacterial deposition and killing may be related to different actions on arachidonic acid metabolism. We speculate that indomethacin may redirect arachidonic acid metabolism to favor increased synthesis of leukotriene B, and other lipoxygenase products that, in turn, recruit additional phagocytes to the lung and/or "prime" these cells for the antimicrobial response directed against GBS (17) . Numerous additional experiments will be needed to resolve this hypothesis.
A surprising observation in the present study is that OKY-046 was associated with substantial increases in hepatic bacterial deposition and viability. As alluded to previously, such an alteration could be ascribed in part to changes in hepatic blood flow associated with thromboxane synthase inhibition; additional studies will be required to address this issue. The overall consequences of the OKY-046-induced increases in hepatic GBS deposition and viability are difficult to assess. In the infant piglet, hepatic bacterial deposition is relatively modest, ranging from about 40 to 8% in our series of studies (5, 6, 18) . The efficacy of bacterial killing also is somewhat less in the liver than in the lung (5, 6, 18) . Consequently, impaired hepatic bacterial clearance associated with OKY-046 might not greatly increase the risk of sepsis in infant piglets and, perhaps, in other species in whom hepatic bacterial clearance is a modest component of the integrated defense mechanism. However, in species such as humans, in whom hepatic bacterial clearance mechanisms predominate over other organs in most instances (19) , the effect of OKY-046 might be significant. At present, we have no cogent explanation for impairment of hepatic bacterial clearance by OKY-046. Both the consequences and mechanism of these effects of OKY-046 will require additional study.
In summary, results of the present study indicate that indomethacin fails to impair pulmonary bacterial clearance of GBS in the infant piglet; augmented pulmonary bacterial deposition and a tendency toward enhanced bacterial killing were noted. These observations suggest that prostaglandin H synthase-derived oxygen radicals do not contribute to pulmonary microbicidal activity directed against GBS. In addition, keeping in mind the difficulties in extrapolation from the laboratory setting to human disease, it seems unlikely that exploration of prostaglandin H synthase inhibition as a strategy for management of pulmonary hypertension in septic neonates will be hampered by impairment of oxygen radical-dependent host microbial defense mechanisms.
